POH 9/1694 -4454.

William Chapman Esq Private Secretary 10 Downing Street LONDON SW1A 2AA

Richmond House 79 Whitehall London SW1A 2NS Telephone 071 210 3000 From the Secretary of State for Health

15. December 1992

HIGH PURITY FACTOR VIII PRODUCTS

You will recall that I advised you that the Secretary of State and the Chief Medical Officer were reconsidering the issue of funding for high purity factor VIII products in light of new data.

The CMO has now written to all Haemophilia Centre Directors and others explaining the change in decision stating that in light of new evidence, if treating clinicians feel that the use of high purity factor VIII products have benefits in terms of HIV infection as well as Haemophilia per se, then the price differential between high and intermediate purity factor VIII products for HIV positive haemophiliacs would be an appropriate use of earmarked AIDS funds.

I attach a copy of the CMO's letter and revised drafts reflecting this change of view.

GRO-C

GINA WAKEMAN Private Secretary